The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A

The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A

A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Subjects were randomized to either receive two tablets of soy isoflavone (100 mg/day) or placebo. At week 12, the serum levels of alanine amino transferase (ALT),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2024-03, Vol.14 (1), p.5134-5134, Article 5134
Hauptverfasser: Neshatbini Tehrani, Asal, Hatami, Behzad, Helli, Bizhan, Yari, Zahra, Daftari, Ghazal, Salehpour, Amin, Hedayati, Mehdi, Khalili, Elmira, Hosseini, Seyed Ahmad, Hekmatdoost, Azita
Format: Artikel
Sprache:eng
Schlagworte:
692/308
692/4020
692/699
alpha-2-HS-Glycoprotein
Clinical trials
Fatty liver
Fibroblast Growth Factors
Fibrosis
Humanities and Social Sciences
Humans
Isoflavones
Liver
Liver diseases
multidisciplinary
Non-alcoholic Fatty Liver Disease - drug therapy
Placebos
Science
Science (multidisciplinary)
Serum levels
Soybeans
Steatosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Subjects were randomized to either receive two tablets of soy isoflavone (100 mg/day) or placebo. At week 12, the serum levels of alanine amino transferase (ALT), aspartate amino transferase (AST) and controlled attenuation parameter (CAP) score were significantly decreased only in the soy isoflavone group (P 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-55747-6